# Pharmacoeconomics Basics

> Pharmacoeconomics basics notes for Pharmacy: direct, indirect and intangible costs, CEA, CUA, CBA, CMA, ICER and QALY explained with worked examples for PCI B.Pharm exams.

- Canonical URL: https://prepelephant.com/topics/allied/pharmacy/pharmacoeconomics-basics
- Exam / course: Allied Health · Subject: Pharmacy
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Pharmacoeconomics Basics", PrepElephant, https://prepelephant.com/topics/allied/pharmacy/pharmacoeconomics-basics

## Direct answer
If a new antihypertensive costs ten times more but prevents twice the strokes, someone must decide whether that exchange is worth it — and pharmacoeconomics is the discipline that makes the exchange measurable. It identifies, measures and compares the costs and outcomes of drug therapy: direct costs (medicines, hospital beds, laboratory tests), indirect costs (lost wages and productivity) and intangible costs (pain and suffering), weighed against outcomes through four standard analyses — cost-minimisation (CMA), cost-effectiveness (CEA), cost-utility (CUA, cost per QALY) and cost-benefit (CBA, both sides in rupees). The incremental cost-effectiveness ratio, ICER, is the single number most papers ask you to compute.

## What you must remember
- Direct medical costs: drug acquisition, dispensing, admissions, consultations, investigations; direct non-medical: travel, food, caregiver expenses; indirect: productivity lost to morbidity and mortality; intangible: suffering, rarely monetised.
- CMA (cost-minimisation analysis): used only when outcomes are proven equivalent — the analysis collapses to choosing the cheapest option.
- CEA (cost-effectiveness analysis): outcomes in natural units — cost per mmHg lowered, per infection cured, per life saved; suits single-outcome comparisons within one disease.
- CUA (cost-utility analysis): outcomes in QALYs — quality-adjusted life years, years of life weighted by quality of life on a 0-1 scale, elicited by instruments such as EQ-5D; allows comparisons across diseases.
- CBA (cost-benefit analysis): outcomes converted to money (willingness to pay), giving a benefit-cost ratio; powerful but ethically contested.
- ICER = (cost of new option − cost of comparator) / (effect of new option − effect of comparator); the price of each extra unit of benefit.
- Perspective matters: patient, hospital, payer or societal — the societal view counts indirect costs and changes conclusions.
- Discounting adjusts future costs and outcomes to present value (commonly around 3 per cent per year in health-economic practice); sensitivity analysis tests whether conclusions survive changed assumptions.
- Applications: formulary decisions by the PTC, pricing under DPCO and NPPA scrutiny, national programme choices, and guiding generic substitution policies such as Janaushadhi procurement.

## An ICER computed and interpreted
Two regimens for a chronic disease: the standard therapy costs Rs 20,000 per patient-year and yields 8 quality-adjusted life years over the horizon; the new therapy costs Rs 80,000 and yields 10. ICER = (80,000 − 20,000)/(10 − 8) = 60,000/2 = Rs 30,000 per additional QALY. Now the decision layer: is Rs 30,000 per QALY acceptable? Countries and payers differ — there is no official Indian threshold, though bodies elsewhere have used benchmarks in the region of one to three times GDP per capita per QALY, a benchmark cited academically rather than adopted as policy. The method conclusion stands regardless: the new therapy is not "expensive" or "cheap" in isolation — it is a defined price for a defined gain, which is exactly what a formulary committee can deliberate on.

Then stress the number, because examiners reward the sensitivity step. If the new therapy's benefit drops to 9 QALYs, the ICER jumps to 60,000; if its price halves, it may dominate outright (cheaper and better). The same arithmetic governs programme decisions — the cost per TB patient cured under a regimen, or per episode of malaria prevented — which is how pharmacoeconomics earns its "fourth arm" place beside clinical evidence in formulary decisions.

## The reasoning errors that fail answers
First, "cheapest is most cost-effective". Cost-effectiveness is a ratio; the cheapest option with poor outcomes can be dominated (more expensive per cure than an alternative), while a costly option can be highly effective per rupee. Second, CEA and CUA conflated: both compare cost to outcome, but CEA uses natural units within a disease while CUA uses QALYs and permits comparisons across diseases — the "which analysis would you use to compare an oncology drug with a cardiac drug?" answer is always CUA.

Third, ignoring perspective: an analysis from the hospital's view may ignore the wage losses the patient bears, and the societal perspective reverses the ranking — state the perspective before computing. Fourth, presenting an ICER without its comparator — an incremental ratio is meaningless unless both arms and the baseline are named. And fifth, forgetting that outcomes, not just costs, carry uncertainty: that is what sensitivity analysis exists to declare.

## Frequently asked questions
### Define pharmacoeconomics and classify costs with examples.
The study that identifies, measures and compares costs and outcomes of drug therapy; direct medical (drug, hospitalisation), direct non-medical (travel), indirect (lost productivity) and intangible (pain, suffering) costs.

### Differentiate CEA, CUA, CBA and CMA.
CMA compares costs when outcomes are identical; CEA uses natural clinical units; CUA uses QALYs for cross-disease comparison; CBA monetises both costs and benefits to give a benefit-cost ratio.

### What is a QALY and why is it useful?
A quality-adjusted life year — one year of perfect health, or the equivalent after weighting by quality of life (0 to 1); it merges survival and quality into one currency for comparing therapies across diseases.

### Compute the ICER if drug A costs Rs 50,000 for 6 QALYs and drug B costs Rs 20,000 for 5 QALYs.
ICER = (50,000 − 20,000)/(6 − 5) = Rs 30,000 per additional QALY gained by choosing A over B.

### Why is sensitivity analysis performed in pharmacoeconomic studies?
Because costs and outcomes are estimates with uncertainty; sensitivity analysis re-runs the calculation across plausible ranges to show whether the conclusion is robust or fragile.